In his penthouse suite in London’s Old Street, under the watchful gaze of a small stone statue of a mushroom god, Christian Angermayer recalls a life-changing experience with psychedelic drugs. It was many years ago, on a tiny island in the Caribbean. The trip was so meaningful for the investor that he decided to back biotech firms using psychedelics to treat depression, anxiety, addiction and other mental-health conditions. Such startups are increasingly catering to corporate clients. A growing number of firms want to offer psychedelics to staff, either for the sake of mental health or to organise a mind-bending corporate retreat.
This surge in interest
→ Continue reading at The Economist
